The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia
Launched by EISAI LIMITED · Sep 13, 2005
Trial Information
Current as of June 19, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Patients with an established diagnosis of PD and dementia, who fulfill all of the inclusion criteria and none of the exclusion criteria listed below, will be eligible for enrolment into this study.
- • Best efforts must be made on clinical grounds to exclude patients with DLB and AD. The key inclusion criteria in this respect is the onset of dementia documented to have occurred at least 1 year after the diagnosis of PD.
About Eisai Limited
Eisai Limited is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative therapies to improve the lives of patients worldwide. With a strong focus on neurology and oncology, Eisai leverages advanced research and development capabilities to create breakthrough treatments that address unmet medical needs. Committed to patient-centric care, the company emphasizes collaboration and ethical practices in clinical trials, aiming to foster advancements in healthcare while ensuring the highest standards of safety and efficacy. Eisai Limited's mission is to contribute to the health and well-being of society through its comprehensive portfolio of medicines and ongoing commitment to scientific excellence.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamburg, Hambug, Germany
Wolfach, , Germany
Belfast, , Ireland
Blackpool, , Ireland
Patients applied
Trial Officials
Jina Schwartz
Study Director
Eisai Limited
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials